In vivo detection of a xenon-binding cage molecule
US11229712B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 30, 2017 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Mar 31, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC01B23/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Xenon based biosensors have the potential to detect and localize biomarkers associated with a wide variety of diseases. The development and nuclear magnetic resonance (NMR) characterization of cage molecules which encapsulate hyperpolarized xenon is imperative for the development of these xenon biosensors. We acquired 129Xe NMR spectra, and magnetic resonance images and a HyperCEST saturation map of cucurbituril (CB6) in whole bovine blood. We observed a mean HyperCEST depletion of 84% (n=5) at a concentration of 5 mM and 74% at 2.5 mM. Additionally, we collected these data using a pulsed HyperCEST saturation pre-pulse train with a SAR of 0.025 W/kg which will minimize any potential RF heating in animal or human tissue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.